pac

PAC is a chemical conjugate consisting of an ADCs linker and PROTACs linked to an antibody. When PAC is conjugated to an antibody, it exhibits enhanced degradation of estrogen receptor-alpha (ERα) in comparison to PROTAC alone.

PROTAC BRD4 degrader for PAC-1 (compound 5) is a chimeric BET degrader GNE-987 conjugated with a disulfide-containing linker[1]. This PROTAC-linker conjugate specifically targets and degrades BRD4, enabling selective proteolysis of PAC-1.

7-O-(Amino-PEG4)-paclitaxel is a PEG-based linker used in PROTACs to connect two essential ligands, facilitating selective protein degradation through the ubiquitin-proteasome system in cells.

7-O-(Cbz-N-amido-PEG4)-paclitaxel is a PEG-based linker for PROTACs that connects two essential ligands, facilitating the formation of PROTAC molecules and enabling selective protein degradation through the ubiquitin-proteasome system within cells.

Paclitaxel-SMCC is a paclitaxel derivative with a SMCC linker. (Succinimidyl-4-( N -maleimidomethyl)cyclohexane-1-carboxylate). Paclitaxel-SMCC can be used to synthesize Paclitaxel bioconjugates with enzymes, antobodies, antigens and other biopolymers. Pa

Paclitaxel-MVCP ( MC-val-cit-pab-paclitaxel )is a paclitaxel derivative with an MC-Val-Cit-PAB linker, which can be used for the preparation of Paclitaxel conjugates for drug delivery and nanomedicine research.

Paclitaxel-Succinic acid (paclitaxel-succinate , paclitaxel-semisucinic acid)is a paclitaxel derivative with a succinic acid linker. Paclitaxel-Succinic acid can be used to prepare paclitaxel conjugates for drug delivery and nanomedicine research.

(S)-GNE-987 binds to the BRD4 BD1(IC50=4 nM) and BD2 (3.9 nM) bromodomains and can be used to design PROTAC-Antibody Conjugate (PAC).

PROTAC ER Degrader-2 serves as a synthesis intermediate for the production of PAC, a compound that incorporates the ADCs linker and PROTACs, which are subsequently conjugated to an antibody. PAC, exhibits a greater capability to degrade estrogen receptor-alpha (ERα) compared to PROTAC (without the presence of an antibody)[1].

PROTAC ER Degrader-3, an intermediate for the synthesis of PAC, specifically compound LP2. PAC serves as the linker for ADCs and PROTACs that are conjugated to an antibody. Notably, when PAC is conjugated to an antibody, it exhibits enhanced degradation of estrogen receptor-alpha (ERα) compared to PROTAC alone [1].

MC-(β-Ala)-PABC-(β-D-GlcUA)-amide-PEG1-CH2-CC-885 (Comp Ie) serves as a neodegrader conjugate instrumental in the synthesis of antibody neoDegrader conjugate (AnDC) [1].

PROTAC BRD4 Degrader-5-CO-PEG3-N3 (Compound 2) is a PROTAC-linker conjugate utilized in PAC, comprising the BRD4 degrader GNE-987 connected with a 3-PEG linker. This compound serves as a click chemistry reagent, featuring an Azide group capable of undergoing copper-catalyzed azide-alkyne cycloaddition reactions (CuAAc) with molecules containing an Alkyne group. Additionally, it can participate in strain-promoted alkyne-azide cycloaddition reactions (SPAAC) with molecules that possess DBCO or BCN groups.